JPWO2020243443A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020243443A5 JPWO2020243443A5 JP2021570762A JP2021570762A JPWO2020243443A5 JP WO2020243443 A5 JPWO2020243443 A5 JP WO2020243443A5 JP 2021570762 A JP2021570762 A JP 2021570762A JP 2021570762 A JP2021570762 A JP 2021570762A JP WO2020243443 A5 JPWO2020243443 A5 JP WO2020243443A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- alk7
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 204
- 102100034135 Activin receptor type-1C Human genes 0.000 claims description 139
- 101000799193 Homo sapiens Activin receptor type-1C Proteins 0.000 claims description 139
- 210000004027 cell Anatomy 0.000 claims description 27
- 238000006467 substitution reaction Methods 0.000 claims description 21
- 238000012217 deletion Methods 0.000 claims description 19
- 230000037430 deletion Effects 0.000 claims description 19
- 238000003780 insertion Methods 0.000 claims description 19
- 230000037431 insertion Effects 0.000 claims description 19
- 239000008194 pharmaceutical composition Substances 0.000 claims description 19
- 239000003446 ligand Substances 0.000 claims description 16
- 230000004130 lipolysis Effects 0.000 claims description 16
- 102000004169 proteins and genes Human genes 0.000 claims description 16
- 108090000623 proteins and genes Proteins 0.000 claims description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 15
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims description 12
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims description 12
- 108010023079 activin B Proteins 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 12
- 102000039446 nucleic acids Human genes 0.000 claims description 12
- 108020004707 nucleic acids Proteins 0.000 claims description 12
- 150000007523 nucleic acids Chemical class 0.000 claims description 12
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims description 12
- 102100040897 Embryonic growth/differentiation factor 1 Human genes 0.000 claims description 10
- 102100035364 Growth/differentiation factor 3 Human genes 0.000 claims description 10
- 102100039939 Growth/differentiation factor 8 Human genes 0.000 claims description 10
- 101000893552 Homo sapiens Embryonic growth/differentiation factor 1 Proteins 0.000 claims description 10
- 101001023986 Homo sapiens Growth/differentiation factor 3 Proteins 0.000 claims description 10
- 101000886562 Homo sapiens Growth/differentiation factor 8 Proteins 0.000 claims description 10
- 108020003175 receptors Proteins 0.000 claims description 10
- 201000010099 disease Diseases 0.000 claims description 9
- 108010059616 Activins Proteins 0.000 claims description 8
- 102100026818 Inhibin beta E chain Human genes 0.000 claims description 8
- 239000000488 activin Substances 0.000 claims description 8
- 210000001789 adipocyte Anatomy 0.000 claims description 8
- 150000001413 amino acids Chemical class 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 6
- 206010061218 Inflammation Diseases 0.000 claims description 6
- 101100437153 Rattus norvegicus Acvr2b gene Proteins 0.000 claims description 6
- 230000003042 antagnostic effect Effects 0.000 claims description 6
- 208000035475 disorder Diseases 0.000 claims description 6
- 230000004054 inflammatory process Effects 0.000 claims description 6
- 230000001404 mediated effect Effects 0.000 claims description 6
- 208000004611 Abdominal Obesity Diseases 0.000 claims description 5
- 208000032928 Dyslipidaemia Diseases 0.000 claims description 5
- 208000035150 Hypercholesterolemia Diseases 0.000 claims description 5
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 5
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 5
- 208000017170 Lipid metabolism disease Diseases 0.000 claims description 5
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 5
- 230000035772 mutation Effects 0.000 claims description 5
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 5
- 206010003210 Arteriosclerosis Diseases 0.000 claims description 4
- 210000000577 adipose tissue Anatomy 0.000 claims description 4
- 208000011775 arteriosclerosis disease Diseases 0.000 claims description 4
- 238000003556 assay Methods 0.000 claims description 4
- 230000015572 biosynthetic process Effects 0.000 claims description 4
- 210000001593 brown adipocyte Anatomy 0.000 claims description 4
- 239000012636 effector Substances 0.000 claims description 4
- 230000000694 effects Effects 0.000 claims description 4
- 239000012634 fragment Substances 0.000 claims description 4
- 230000005764 inhibitory process Effects 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 230000002611 ovarian Effects 0.000 claims description 4
- 230000026731 phosphorylation Effects 0.000 claims description 4
- 238000006366 phosphorylation reaction Methods 0.000 claims description 4
- 230000011664 signaling Effects 0.000 claims description 4
- 208000011580 syndromic disease Diseases 0.000 claims description 4
- 210000000636 white adipocyte Anatomy 0.000 claims description 4
- 206010007559 Cardiac failure congestive Diseases 0.000 claims description 3
- 206010065941 Central obesity Diseases 0.000 claims description 3
- 206010009944 Colon cancer Diseases 0.000 claims description 3
- 206010014733 Endometrial cancer Diseases 0.000 claims description 3
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 3
- 206010019280 Heart failures Diseases 0.000 claims description 3
- 208000018565 Hemochromatosis Diseases 0.000 claims description 3
- 206010060378 Hyperinsulinaemia Diseases 0.000 claims description 3
- 208000031226 Hyperlipidaemia Diseases 0.000 claims description 3
- 206010020772 Hypertension Diseases 0.000 claims description 3
- 108060003951 Immunoglobulin Proteins 0.000 claims description 3
- 206010022489 Insulin Resistance Diseases 0.000 claims description 3
- 206010065973 Iron Overload Diseases 0.000 claims description 3
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 3
- 108090001030 Lipoproteins Proteins 0.000 claims description 3
- 102000004895 Lipoproteins Human genes 0.000 claims description 3
- 208000001145 Metabolic Syndrome Diseases 0.000 claims description 3
- 208000008589 Obesity Diseases 0.000 claims description 3
- 208000031964 Other metabolic disease Diseases 0.000 claims description 3
- 206010033307 Overweight Diseases 0.000 claims description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 3
- 208000018262 Peripheral vascular disease Diseases 0.000 claims description 3
- 206010038389 Renal cancer Diseases 0.000 claims description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 3
- 208000006011 Stroke Diseases 0.000 claims description 3
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 claims description 3
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 claims description 3
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 3
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims description 3
- 230000005856 abnormality Effects 0.000 claims description 3
- 102000023732 binding proteins Human genes 0.000 claims description 3
- 108091008324 binding proteins Proteins 0.000 claims description 3
- 210000000481 breast Anatomy 0.000 claims description 3
- 210000001072 colon Anatomy 0.000 claims description 3
- 208000029742 colonic neoplasm Diseases 0.000 claims description 3
- 208000029078 coronary artery disease Diseases 0.000 claims description 3
- 230000002357 endometrial effect Effects 0.000 claims description 3
- 208000010706 fatty liver disease Diseases 0.000 claims description 3
- 206010017758 gastric cancer Diseases 0.000 claims description 3
- 230000002496 gastric effect Effects 0.000 claims description 3
- 208000019622 heart disease Diseases 0.000 claims description 3
- 208000006454 hepatitis Diseases 0.000 claims description 3
- 201000001421 hyperglycemia Diseases 0.000 claims description 3
- 230000003451 hyperinsulinaemic effect Effects 0.000 claims description 3
- 201000008980 hyperinsulinism Diseases 0.000 claims description 3
- 102000018358 immunoglobulin Human genes 0.000 claims description 3
- 201000010982 kidney cancer Diseases 0.000 claims description 3
- 210000004185 liver Anatomy 0.000 claims description 3
- 201000007270 liver cancer Diseases 0.000 claims description 3
- 208000018191 liver inflammation Diseases 0.000 claims description 3
- 208000014018 liver neoplasm Diseases 0.000 claims description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 201000001119 neuropathy Diseases 0.000 claims description 3
- 230000007823 neuropathy Effects 0.000 claims description 3
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims description 3
- 235000020824 obesity Nutrition 0.000 claims description 3
- 201000002528 pancreatic cancer Diseases 0.000 claims description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 3
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 3
- 208000037803 restenosis Diseases 0.000 claims description 3
- 201000011549 stomach cancer Diseases 0.000 claims description 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 3
- 229940116269 uric acid Drugs 0.000 claims description 3
- 206010046766 uterine cancer Diseases 0.000 claims description 3
- 230000002792 vascular Effects 0.000 claims description 3
- 201000001320 Atherosclerosis Diseases 0.000 claims description 2
- 241000699802 Cricetulus griseus Species 0.000 claims description 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims description 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims description 2
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims description 2
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims description 2
- 102100025751 Mothers against decapentaplegic homolog 2 Human genes 0.000 claims description 2
- 101710143123 Mothers against decapentaplegic homolog 2 Proteins 0.000 claims description 2
- 102100025748 Mothers against decapentaplegic homolog 3 Human genes 0.000 claims description 2
- 101710143111 Mothers against decapentaplegic homolog 3 Proteins 0.000 claims description 2
- 201000010769 Prader-Willi syndrome Diseases 0.000 claims description 2
- 208000017442 Retinal disease Diseases 0.000 claims description 2
- 206010038923 Retinopathy Diseases 0.000 claims description 2
- 230000003187 abdominal effect Effects 0.000 claims description 2
- 108010023082 activin A Proteins 0.000 claims description 2
- 238000004458 analytical method Methods 0.000 claims description 2
- 239000002246 antineoplastic agent Substances 0.000 claims description 2
- 238000002648 combination therapy Methods 0.000 claims description 2
- 239000002299 complementary DNA Substances 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 229940127089 cytotoxic agent Drugs 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 210000005260 human cell Anatomy 0.000 claims description 2
- 238000002372 labelling Methods 0.000 claims description 2
- 230000004048 modification Effects 0.000 claims description 2
- 238000012986 modification Methods 0.000 claims description 2
- 210000001672 ovary Anatomy 0.000 claims description 2
- 229940124597 therapeutic agent Drugs 0.000 claims description 2
- 239000003053 toxin Substances 0.000 claims description 2
- 231100000765 toxin Toxicity 0.000 claims description 2
- 108700012359 toxins Proteins 0.000 claims description 2
- 150000003626 triacylglycerols Chemical class 0.000 claims description 2
- -1 triglycerides lipid Chemical class 0.000 claims description 2
- 208000002705 Glucose Intolerance Diseases 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 201000009104 prediabetes syndrome Diseases 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 101100369076 Mus musculus Tdgf1 gene Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 230000000923 atherogenic effect Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 208000006575 hypertriglyceridemia Diseases 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962854619P | 2019-05-30 | 2019-05-30 | |
| US62/854,619 | 2019-05-30 | ||
| PCT/US2020/035141 WO2020243443A1 (en) | 2019-05-30 | 2020-05-29 | Alk7 binding proteins and uses thereof |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022534514A JP2022534514A (ja) | 2022-08-01 |
| JP2022534514A5 JP2022534514A5 (https=) | 2023-06-06 |
| JPWO2020243443A5 true JPWO2020243443A5 (https=) | 2023-06-06 |
| JP7617036B2 JP7617036B2 (ja) | 2025-01-17 |
Family
ID=73553930
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021570762A Active JP7617036B2 (ja) | 2019-05-30 | 2020-05-29 | Ａｌｋ７結合タンパク質及びその使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US12365736B2 (https=) |
| EP (1) | EP3976656A4 (https=) |
| JP (1) | JP7617036B2 (https=) |
| KR (1) | KR20220016136A (https=) |
| CN (1) | CN114245805A (https=) |
| AU (1) | AU2020282764A1 (https=) |
| CA (1) | CA3142147A1 (https=) |
| WO (1) | WO2020243443A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7617036B2 (ja) | 2019-05-30 | 2025-01-17 | アクセレロン ファーマ インコーポレーテッド | Ａｌｋ７結合タンパク質及びその使用 |
| JP2024532345A (ja) * | 2021-09-03 | 2024-09-05 | ラエクナ セラピューティクス シャンハイ カンパニー リミテッド | 抗ａｃｖｒ２ａ抗体及びその使用 |
| WO2025155971A1 (en) * | 2024-01-19 | 2025-07-24 | Immunomic Therapeutics, Inc | Anti-activin receptor 1c (alk-7) receptor antibodies |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116217731B (zh) * | 2016-04-22 | 2025-12-30 | 艾科赛扬制药股份有限公司 | Alk7结合蛋白及其用途 |
| BR112020007751A2 (pt) * | 2017-10-25 | 2020-10-20 | Acceleron Pharma Inc. | proteínas de ligação de alk7 e usos das mesmas |
| JP7617036B2 (ja) | 2019-05-30 | 2025-01-17 | アクセレロン ファーマ インコーポレーテッド | Ａｌｋ７結合タンパク質及びその使用 |
-
2020
- 2020-05-29 JP JP2021570762A patent/JP7617036B2/ja active Active
- 2020-05-29 KR KR1020217042386A patent/KR20220016136A/ko active Pending
- 2020-05-29 EP EP20813963.4A patent/EP3976656A4/en active Pending
- 2020-05-29 CN CN202080043141.5A patent/CN114245805A/zh active Pending
- 2020-05-29 WO PCT/US2020/035141 patent/WO2020243443A1/en not_active Ceased
- 2020-05-29 CA CA3142147A patent/CA3142147A1/en active Pending
- 2020-05-29 US US17/615,508 patent/US12365736B2/en active Active
- 2020-05-29 AU AU2020282764A patent/AU2020282764A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019515676A5 (https=) | ||
| CN102149730B (zh) | Fgf-r4受体特异性拮抗剂 | |
| JP6931750B2 (ja) | 抗ｉｌ−１７ａ／ｆ抗体を用いた治療方法 | |
| JP7499228B2 (ja) | 神経成長因子に対するモノクローナル抗体、並びにそれをコードする遺伝子及びその使用 | |
| JP2024026159A5 (https=) | ||
| JP2010043089A5 (https=) | ||
| JP2017184753A (ja) | ＩＬ７受容体のα鎖に対する抗体‐薬剤候補物質の製造におけるこれらの使用 | |
| TW202037603A (zh) | 異二聚免疫球蛋白 | |
| IL239674A (en) | Molecules bind to the human ox40 receptor | |
| US10696741B2 (en) | Anti-IL-22R antibodies | |
| JP2019513015A5 (https=) | ||
| JP6738432B2 (ja) | 抗ｐｃｓｋ９抗体およびその使用 | |
| WO2013147213A1 (ja) | ＣＤＲ改変抗Ｓｉｇｌｅｃ－１５抗体 | |
| JP2021500895A5 (https=) | ||
| WO2018067819A1 (en) | Compositions and methods for treatment of cancers | |
| TW202332691A (zh) | Ige調節的疾病的治療 | |
| KR20240057529A (ko) | 신규 항-cdcp1 항체 및 이의 용도 | |
| TW202339799A (zh) | 使用抗人類ｇｐｖｉ抗體抑制血小板凝集 | |
| KR102063341B1 (ko) | Icam-1에 특이적으로 결합하는 항체 및 그의 용도 | |
| JP7510208B2 (ja) | 抗ＴｒｋＡ抗体又はその抗原結合フラグメント、その調製方法及び使用 | |
| JPWO2020243443A5 (https=) | ||
| JPWO2020243448A5 (https=) | ||
| Bakherad et al. | Engineering an anti-granulocyte colony stimulating factor receptor nanobody for improved affinity | |
| AU2014271291A1 (en) | Fgf-r4 receptor-specific antagonists | |
| WO2024096022A1 (ja) | 抗アディポネクチン受容体抗体及びその利用 |